CPT1A and colorectal cancer: Lin et al. (2021) engineered iRGD-modified exosomes and encapsulated them with siRNA targeting CPT1A in colorectal cancer cells leading to CPT1A knockdown, suppressing FAO and reversing oxaliplatin resistance. iRGD-modified exosomes significantly suppressed the expression of CPT1A in tumor tissues, reversed oxaliplatin resistance, and inhibited tumor growth by inhibiting FAO with high safety in vivo.